Recently Viewed
Clear AllValue Research Rating
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
₹61,967 Cr
Revenue (TTM)
₹16,827 Cr
Net Profit (TTM)
₹604 Cr
ROE
7 %
ROCE
7.4 %
P/E Ratio
102.6
P/B Ratio
1.6
Industry P/E
29.25
EV/EBITDA
19.2
Div. Yield
0.1 %
Debt to Equity
0.8
Book Value
₹233.5
EPS
₹0.1
Face value
5
Shares outstanding
1,620,907,773
CFO
₹15,314.30 Cr
EBITDA
₹15,631.90 Cr
Net Profit
₹8,640.70 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Biocon
| -2.9 | 0.9 | -0.9 | 14.8 | 23.7 | -0.3 | 17.3 |
|
BSE Healthcare
| -1.7 | -1.1 | -1.9 | 7.5 | 25.6 | 15.6 | 10.7 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Biocon
| 6.8 | 43.0 | -4.7 | -28.2 | -21.7 | 58.0 | -6.1 |
|
BSE Mid Cap
| 1.1 | 25.8 | 45.5 | 1.4 | 39.2 | 19.9 | -3.0 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 | 20.9 | 61.4 | -3.5 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Biocon
|
382.6 | 61,967.3 | 16,827.4 | 629.6 | 9.6 | -0.1 | 102.6 | 1.6 |
| 26,375.0 | 55,882.2 | 6,824.1 | 1,524.1 | 25.9 | 37 | 36.7 | 12.7 | |
| 5,351.5 | 63,950.5 | 14,252.7 | 2,424.5 | 17.5 | 19 | 27 | 4.6 | |
| 1,269.0 | 73,703.7 | 33,181.9 | 3,513.2 | 15.4 | 10.4 | 21.1 | 2.1 | |
| 2,437.6 | 41,252.1 | 3,800.7 | 1,021.0 | 32.2 | 55 | 40.4 | 20.6 | |
| 1,543.6 | 39,123.7 | 9,504.5 | 947.8 | 15.9 | 14.6 | 43 | 5.0 | |
| 2,302.4 | 1,05,236.5 | 26,150.5 | 4,669.2 | 24.2 | 27 | 22.7 | 5.1 | |
| 2,103.1 | 86,793.0 | 13,914.1 | 1,792.3 | 17.8 | 12.6 | 48.8 | 5.5 | |
| 1,778.3 | 4,26,781.7 | 56,809.1 | 11,001.4 | 23.9 | 16.2 | 39.1 | 5.3 | |
| 899.6 | 90,435.3 | 26,089.3 | 4,933.9 | 24.7 | 21 | 18.3 | 3.4 |
1 min read•By Research Desk
2 min read•By Value Research
5 min read•By Research Desk
2 min read•By Research Desk
Biocon Limited, together with its subsidiaries, manufactures and sells biotechnology products and research services in India, the United States, Ireland, rest of the European Union, and internationally. It operates through Generics, Biosimilars, and... Research segments. The company offers generic formulations and API products, including cardiovascular, anti-diabetics, obesity, multiple sclerosis, anti-fungal, anti-cancer, immunosuppressants, and specialty molecules; and biosimilars products consisting of pegfilgrastim, trastuzumab, bevacizumab, adalimumab, etanercept, ustekinumab, glargine, aspart, insulins, and aflibercept. It also provides integrated discovery, development, and manufacturing services to pharmaceutical, biotechnology, animal healthcare, consumer goods, and agrochemical companies. In addition, the company offers enzyme, biopharmaceutical, and medicinal goods; contract research and manufacturing services, and other research and development in the fields of pharmaceuticals, drug discovery, biotechnology pharmaceuticals, and medicinal sciences, etc.; clinical research; and business support and development, and marketing services. Biocon Limited was incorporated in 1978 and is headquartered in Bengaluru, India. Read more
Incorporated
1978
Chairman
Kiran Mazumdar-Shaw
Managing Director
Siddharth Mittal
Headquarters
Bengaluru, Karnataka
Website
Looking for more details about Biocon Ltd.’s IPO? Explore our IPO Details page.
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
The share price of Biocon Ltd is ₹382.60 (NSE) and ₹382.30 (BSE) as of 18-Mar-2026 IST. Biocon Ltd has given a return of 23.67% in the last 3 years.
The P/E ratio of Biocon Ltd is 102.56 times as on 18-Mar-2026, a 251 premium to its peers’ median range of 29.25 times.
The P/B ratio of Biocon Ltd is 1.64 times as on 18-Mar-2026, a 64 discount to its peers’ median range of 4.56 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
40.43
|
1.93
|
|
2024
|
31.01
|
1.63
|
|
2023
|
53.54
|
1.41
|
|
2022
|
61.95
|
4.88
|
|
2021
|
66.25
|
6.57
|
The 52-week high and low of Biocon Ltd are Rs 424.95 and Rs 299.00 as of 19-Mar-2026.
Biocon Ltd has a market capitalisation of ₹ 61,967 Cr as on 18-Mar-2026. As per SEBI classification, it is a Mid Cap company.
Before investing in Biocon Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
₹5.05
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.